FrancophonIA/ELRC3.0 huggingface dataset:
English: The cells in giant cell tumour of bone are also activated via RANKL, and treatment with denosumab prevents them from growing and breaking down bone, allowing normal bone to replace the tumour.
Estonian: RANKL aktiveerib ka hiidrakulise luukasvaja rakud ning ravi denosumaabiga takistab nende kasvamist ja luukoe lagundamist, võimaldades tervel luukoel kasvaja asendada.
English: Two main studies looked at the effect of Xgeva in adults or full-grown adolescents with giant cell tumour of bone that was unsuitable for surgery or in whom surgery would have resulted in severe complications like amputation of a limb.
Estonian: Kahes põhiuuringus vaadeldi Xgeva toimet täiskasvanutel või väljaarenenud luustikuga noorukitel, kellel oli hiidrakuline luukasvaja, mida ei saanud ravida kirurgiliselt või mille kirurgiline ravi oleks põhjustanud raskeid kahjustusi, nagu jäseme amputatsioon.
English: The Agency considered that Xgeva was effective in preventing bone-related events and was less toxic to the kidneys and easier to use than existing treatments.
Estonian: Amet leidis, et Xgeva oli luustikuga seotud haigusjuhtude ärahoidmisel efektiivne ning neerudele vähem toksiline, samuti on seda võrreldes teiste olemasolevate ravimitega lihtsam kasutada.
English: For the full list of side effects and restrictions with Xgeva, see the package leaflet.
Estonian: Xgeva kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Other common side effects (seen in up to 1 patient in 10) are development of another form of cancer in patients with advanced cancer, hypophosphataemia (low levels of phosphate in the blood), excessive sweating, tooth loss and osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth and loose teeth).
Estonian: Muud sagedad kõrvalnähud (esinenud kuni 1 patsiendil 10st) on muu vähiliigi teke kaugelearenenud vähiga patsientidel, hüpofosfateemia (liiga väike fosfaadisisaldus veres), liighigistamine, hammaste väljalangemine ja lõualuu osteonekroos (lõualuude kahjustus, mis võib tekitada valu, suuhaavandeid ja hammaste logisemist).
English: All the studies looked at the risk of patients having a first ‘skeletal-related event' (such as a fracture, pressure on the spinal cord or the need for radiotherapy or surgery to the bone) during the study period by measuring how long it took for this event to happen.
Estonian: Kõikides uuringutes vaadeldi patsientidel esmaste luustikuga seotud haigusjuhtude (nt murd, seljaaju kompressioon või kiiritusravi või kirurgilise luuravi vajadus) tekkeriski uuringuperioodil, hinnates aega kõnealuse haigusjuhuni.
English: In another study involving 1,718 patients with newly diagnosed multiple myeloma, Xgeva was as effective as zoledronic acid in delaying the patients' first skeletal-related event.
Estonian: Veel ühes uuringus, milles osales 1718 hulgimüeloomi esmadiagnoosiga patsienti, oli Xgeva esmaste luustikuga seotud haigusjuhtude edasilükkamisel sama efektiivne kui soledroonhape.
English: The third study involved 1,776 patients with advanced solid tumours in various parts of the body or with multiple myeloma (a cancer of the bone marrow).
Estonian: Kolmandas uuringus osales 1776 eri kehaosade kaugelearenenud soliidtuumoritega või hulgimüeloomiga (teatav luuüdivähk) patsienti.
English: Xgeva must not be used in patients with wounds from dental or mouth surgery have not yet healed, or in people with severe, untreated hypocalcaemia.
Estonian: Xgevat ei tohi kasutada patsiendid, kellel on hamba- või suuoperatsioonist paranemata haavad, ega raske, ravimata hüpokaltseemiaga patsiendid.
English: What benefits of Xgeva have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Xgeva kasulikkus?
English: These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery.
Estonian: Sellised luukahjustused on luumurrud, seljaaju kompressioon (seljaaju pitsumine, mis on põhjustatud ümbritseva luu kahjustusest) või kiiritusravi või kirurgilist ravi vajavad luuprobleemid.
English: The active substance in Xgeva, denosumab, is a monoclonal antibody which has been designed to recognise and attach to a protein called RANKL.
Estonian: Xgeva toimeaine denosumaab on monoklonaalne antikeha, mis tunneb ära RANKLiks nimetatava valgu ja seondub sellega.
English: The most common side effects with Xgeva (seen in more than 1 patient in 10) are hypocalcaemia (low levels of calcium in the blood), pain in the muscles and bones, dyspnoea (difficulty breathing) and diarrhoea.
Estonian: Xgeva kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on hüpokaltseemia (liiga väike kaltsiumisisaldus veres), lihase- ja luuvalu, düspnoe (hingamisraskused) ja kõhulahtisus.
English: The first study involved 2,046 patients with breast cancer and the second study involved 1,901 men with prostate cancer which did not respond to hormonal treatment.
Estonian: Esimeses uuringus osales 2046 rinnavähiga patsienti ja teises uuringus 1901 ravile mitteallunud eesnäärmevähiga meest.
English: Patients should take calcium and vitamin D supplements while being treated with Xgeva.
Estonian: Xgevaga toimuva ravi ajal peavad patsiendid võtma lisaks kaltsiumi ja D-vitamiini.
English: How is Xgeva used?
Estonian: Kuidas Xgevat kasutatakse?
English: To prevent bone complications in cancer that has spread to the bone, 120 mg is given once every 4 weeks as a single injection under the skin in the thigh, abdomen (belly) or upper arm.
Estonian: Luudesse levinud vähi korral luukahjustuste ennetamiseks manustatakse Xgevat annuses 120 mg üks kord iga 4 nädala järel ühekordse nahaaluse süstina reie-, kõhu- või õlavarre piirkonda.
English: Xgeva can only be obtained with a prescription.
Estonian: Xgeva on retseptiravim.
English: Treatment of giant cell tumour of bone
Estonian: Hiidrakulise luukasvaja ravi
English: This protein activates osteoclasts, the cells in the body that are involved in breaking down bone tissue.
Estonian: RANKL aktiveerib osteoklastid ehk luukoe lagundamises osalevad organismi rakud.
English: Xgeva was compared with zoledronic acid (another medicine used to prevent bone complications) in four main studies in patients with different types of cancer which had spread to the bone.
Estonian: Xgevat võrreldi soledroonhappega (samuti luukahjustuste ennetamise ravim) neljas põhiuuringus, milles osalesid luudesse levinud eri vähiliikidega patsiendid.
English: An overview of Xgeva and why it is authorised in the EU
Estonian: Ülevaade ravimist Xgeva ja ELis müügiloa väljastamise põhjendus
English: By attaching to RANKL and blocking it, denosumab reduces the formation and activity of the osteoclasts.
Estonian: RANKLiga seondumise ja selle blokeerimisega vähendab denosumaab osteoklastide teket ja aktiivsust, vähendades luukoe hõrenemist ning luumurdude ja muude raskete luukahjustuste tekkeriski.
English: In these studies, Xgeva reduced the risk of developing a first skeletal-related event by 18% compared with zoledronic acid.
Estonian: Nendes uuringutes vähendas Xgeva võrreldes soledroonhappega esmaste luustikuga seotud haigusjuhtude tekkeriski 18%.
English: The European Medicines Agency decided that Xgeva's benefits are greater than its risks for patients with cancers that has spread to the bone, and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Xgeva kasulikkus luudesse levinud vähiga patsientidel on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Xgeva is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone.
Estonian: Xgeva on ravim, mida kasutatakse luukahjustuste ennetamiseks luudesse levinud kaugelearenenud vähiga täiskasvanutel.
English: In this study, Xgeva reduced the risk of developing a first skeletal-related event by 16% compared with zoledronic acid.
Estonian: Selles uuringus vähendas Xgeva soledroonhappega võrreldes esmaste luustikuga seotud haigusjuhtude tekkeriski 16%.
English: The Agency considered that the benefits of Xgeva in giant cell tumour of bone were greater than the risks, and recommended that it be authorised for use in the EU.
Estonian: Amet järeldas, et Xgeva kasulikkus hiidrakulise luukasvajaga patsientidel on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: It is available as a solution for injection under the skin.
Estonian: Seda turustatakse süstelahusena nahaaluseks manustamiseks.
English: In patients with giant cell tumour of bone, Xgeva was effective in controlling the disease.
Estonian: Xgeva oli efektiivne ka hiidrakulise luukasvajaga patsientide haiguse reguleerimisel.
English: 17 December 2009 EMA/828729/2009 EMEA/H/C/1063
Estonian: 17. detsember 2009 EMA/828729/2009 EMEA/H/C/1063
English: The company presented results of one main study involving 463 patients undergoing different types of
Estonian: Ettevõte esitas andmed ühe põhiuuringu kohta, milles osales mitmesuguste kirurgiliste operatsioonide 463 patsienti.
English: What is Recothrom?
Estonian: Mis on Recothrom?
English: According to EU requirements, Recothrom should have been compared with a standard treatment that did not contain thrombin.
Estonian: Euroopa Liidu nõuete kohaselt oleks Recothromi pidanud võrdlema tavapärase ravimeetodiga, mis ei sisalda trombiini.
English: EMA/828729/2009
Estonian: Teave müügiloa taotluse tagasivõtmise kohta Recothrom (alfatrombiin) EMA/828729/2009
English: The study compared Recothrom with another medicine containing thrombin and the main measure of effectiveness was the number of patients whose bleeding stopped within 10 minutes.
Estonian: Uuringus võrreldi Recothromi teise trombiini sisaldava ravimiga ja efektiivsuse põhinäitaja oli patsientide arv, kellel verejooks peatus 10 minuti jooksul.
English: Thrombin converts another protein called fibrinogen into smaller units called fibrin.
Estonian: Trombiin lõhustab fibrinogeeniks nimetatava valgu väiksemateks üksusteks (fibriiniks).
English: In addition, not enough evidence was presented to show that Recothrom used with a gelatin sponge was more effective than a sponge alone.
Estonian: Samuti ei olnud küllaldaselt andmeid selle kohta, et Recothrom koos želatiinkäsnaga oleks olnud efektiivsem kui üksnes želatiinkäsn.
English: What are the consequences of the withdrawal for patients in clinical trials or compassionate use programmes using Recothrom?
Estonian: Kuidas mõjutab tagasivõtmine praegu Recothromi kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Recothrom could not have been approved for use in stopping bleeding during surgery where standard surgical techniques are insufficient.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Recothromi kasutamist verejooksu peatamiseks kirurgiliste operatsioonidel, kui tavapärased kirurgilised meetodid on ebapiisavad, ei ole võimalik heaks kiita.
English: The Committee also noted that because the sponge and spray worked differently and should have been studied separately, there was not enough to determine the effects of the spray.
Estonian: Inimravimite komitee leidis ka, et želatiinkäsna ja pihuse toime erines ning neid oleks tulnud seetõttu hinnata eraldi, kuid pihuse efektiivsuse kohta ei olnud esitatud piisavalt andmeid.
English: The company informed the CHMP that at this time there are no ongoing clinical trials or compassionate use programmes with Recothrom in Europe.
Estonian: Ettevõte teatas inimravimite komiteele, et Recothromi kliinilisi uuringuid ega ravimi eriloaga kasutamise programme praegu Euroopas ei toimu.
English: The fibrin particles then stick together, forming clots which help to stop the bleeding.
Estonian: Fibriiniosakesed kleepuvad kokku verehüübeks, mis peatabki verejooksu.
English: On 11 December 2009, Bayer Schering Pharma AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Recothrom, for use in stopping bleeding during surgery where standard surgical techniques are insufficient.
Estonian: 11. detsembril 2009 teatas Bayer Schering Pharma AG ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Recothrom müügiloa taotlus.
English: Recothrom was expected to be used to stop bleeding during an operation when standard surgical techniques are insufficient.
Estonian: Recothromi oli kavatsetud kasutada verejooksu peatamiseks kirurgilistel operatsioonidel, kui tavapärased kirurgilised meetodid on ebapiisavad.
English: Recothrom was expected to be applied to the surgical wounds either using a gelatin sponge soaked with the solution, or by spraying the solution directly into the surgical wound.
Estonian: Recothromi kavatseti kanda kirurgilisele haavale lahusega niisutatud želatiinkäsna abil või pihustades lahust vahetult kirurgilisse haava.
English: Recothrom is a powder and solvent for solution to be applied to a surgical wound.
Estonian: Recothrom on pulber ja lahusti lahuse valmistamiseks, mis kantakse kirurgilisele haavale.
English: The CHMP was concerned that the company provided evidence from specialised surgeries, whereas Recothrom was intended for more general use.
Estonian: Inimravimite komitee leidis, et ettevõte oli esitanud andmed spetsiifiliste kirurgiliste protseduuride kohta, aga taotles Recothromile müügiluba üldisemaks kasutamiseks.
English: The active substance in Recothrom, thrombin alfa, is a copy of thrombin, a protein that is found naturally in the blood.
Estonian: Recothromi toimeaine alfatrombiin on veres leiduva loodusliku valgu trombiini analoog.
English: It contains the active substance thrombin alfa.
Estonian: Ravim sisaldab toimeainena alfatrombiini.
English: Thrombin also helps to make specialised cells in the blood called platelets to stick together, forming clots which also reduce the bleeding.
Estonian: Trombiin soodustab ka trombotsüütide agregatsiooni (kokkukleepumist), mille tulemisel tekivad samuti verehüübed, mis vähendavad verejooksu.
English: How was Recothrom expected to work?
Estonian: Milline on Recothromi eeldatav toime?
English: The effects of Recothrom were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Recothromi toimet muude katsetega.
English: What was Recothrom expected to be used for?
Estonian: Milleks kavatseti Recothromi kasutada?
English: Finally, there were concerns about the medicine that Recothrom was compared with (the comparator) in the main study.
Estonian: Inimravimite komitee ei olnud rahul ka Recothromi põhiuuringus kasutatud võrdlusravimi valikuga.
English: After reconstitution: 4 weeks.
Estonian: Peale lahustamist: 4 nädalat.
English: Austria, Belgium/Luxembourg, Bulgaria, Cyprus, Germany, Denmark, Estonia, Greece, Finland, France, Hungary, Ireland, Italy, Lithuania, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Slovenia, Spain, Sweden, United Kingdom, Iceland, Norway
Estonian: Austria, Belgia/Luksemburg, Bulgaaria, Küpros, Saksamaa, Taani, Eesti, Kreeka, Soome, Prantsusmaa, Ungari, Iirimaa, Itaalia, Leedu, Läti, Malta, Holland, Poola, Portugal, Rumeenia, Sloveenia, Hispaania, Rootsi, Ühendkuningriik, Island, Norra.
English: The mean length of follow-up was 4.8 years.
Estonian: Keskmine jälgimise aeg oli 4,8 aastat.
English: Sector 1, Bucureşti, România
Estonian: Sector 1, Bukarest, Rumeenia
English: 11415 Tallinn, Estonia
Estonian: 11415 Tallinn, Eesti
English: • The follow-up measures as set out in the CHMP Assessment Report
Estonian: • järelmeetmed vastavalt inimravimite komitee hindamisaruandes sätestatule.
English: For patients who can swallow tablets, this dosage form is also available.
Estonian: Patsientide jaoks, kes saavad neelata tablette, on ka see annuse vorm olemas.
English: The National Competent Authorities, coordinated by the Reference Member State, shall ensure the following conditions are fulfilled by the Marketing Authorisation Holder:
Estonian: Riikide pädevad asutused, kelle tegevust koordineerib viiteliikmesriik, tagavad järgmiste tingimuste täitmise müügiloa hoidja poolt:
English: Like all medicines, COZAAR can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka COZAAR põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Shake the suspension prior to each use and return promptly to the refrigerator.
Estonian: Enne igat kasutamist loksutage suspensiooni ja pange see kohe pärast kasutamist tagasi külmkappi.
English: This is a serious but rare side effect, which affects more than 1 out of 10,000 patients but fewer than 1 out of 1,000 patients.
Estonian: See on tõsine, kuid harvaesinev kõrvaltoime, mis võib esineda enam kui ühel patsiendil 10 000-st, kuid vähem kui ühel patsiendil 1000-st.
English: Measures are depending on the time of medicinal product intake and kind and severity of symptoms.
Estonian: Meetmed sõltuvad ravimi manustamise ajast ning sümptomite olemusest ja raskusest.
English: Always take COZAAR exactly as your doctor has instructed you.
Estonian: Võtke COZAAR´i alati täpselt nii, nagu arst on teile rääkinud.
English: You should not take losartan in the first 12 weeks of pregnancy, and you must not take it at all after the 13th week as its use during pregnancy may possibly be harmful to the baby.
Estonian: Losartaani ei tohi võtta esimese 12 rasedusnädala jooksul ja mitte mingil juhul pärast 13. rasedusnädalat, sest nende kasutamine raseduse ajal võib olla lapsele kahjulik.
English: Therefore, the use of losartan is not recommended.
Estonian: Seetõttu ei ole losartaani kasutamine soovitatav.
English: Losartan has been evaluated in clinical studies as follows:
Estonian: Losartaani on hinnatud järgmistes kliinilistes uuringutes:
English: 1407 Sofia, Bulgaria
Estonian: 1407 Sofia, Bulgaaria
English: Your doctor will decide on the appropriate dose of COZAAR, depending on your condition and whether you are taking other medicines.
Estonian: Teie arst otsustab, milline on sobiv COZAAR´i annus teie seisundi ja selle põhjal, kas te võtate teisi ravimeid.
English: The Applicant commits to provide the following information to the National Competent Authority of the Reference Member State for evaluation:
Estonian: müügiloa taotleja kohustub saatma viiteliikmesriigi pädevale asutusele hindamiseks järgmise teabe:
English: Therefore, concomitant use is not recommended (see section 4.5).
Estonian: Seetõttu samaaegset kasutamist ei soovitata (vt lõik 4.5).
English: Other warnings and precautions:
Estonian: Muud hoiatused ja ettevaatusabinõud
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S), ROUTE(S) OF ADMINISTRATION OF THE MEDICINAL PRODUCT(S), MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES
Estonian: LISA I RAVIMI(TE) NIMETUSTE, RAVIMVORMI(DE), TUGEVUS(T)E, MANUSTAMISVIISI(DE), TAOTLEJA(TE), MÜÜGILOA HOIDJA(TE) LOETELU LIIKMESRIIKIDES
English: Infants whose mothers have taken losartan should be closely observed for hypotension.
Estonian: Lapsi, kelle emad on võtnud losartaani, tuleb tähelepanelikult jälgida hüpotensiooni suhtes.
English: This also applies to children 6 to 16 years of age.
Estonian: See kehtib ka 6…16-aastaste laste kohta.
English: Tatoiou Street, Nea Erythraia 14671, Greece
Estonian: Tatoiou Street, Nea Erythraia 14671, Kreeka
English: 00-867 Warsaw, Poland
Estonian: 00-867 Varssavi, Poola
English: Although consideration should be given to initiating therapy with 25 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly.
Estonian: Kuigi tuleb mõelda ravi alustamisele annusega 25 mg üle 75-aastaste patsientide raviks, ei ole annuse kohandamine tavaliselt eakate patsientide puhul vajalik.
English: Taking other medicines: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines and natural products.
Estonian: Palun informeerige oma arsti või apteekrit, kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid või taimseid preparaate ja loodusravi tooteid.
English: The systemic bioavailability of losartan tablets is approximately 33 %.
Estonian: Losartaanitablettide süsteemne biosaadavus on umbes 33%.
English: The solvent contains sorbitol.
Estonian: Lahusti sisaldab sorbitooli.
English: Push the plunger of the syringe completely down.
Estonian: Suruge süstla kolb täiesti alla.
English: The patients should have a left ventricular ejection fraction ≤ 40 % and should be stabilised under the treatment of the chronic heart failure.
Estonian: Patsientide vasaku vatsakese väljutusfraktsioon peab olema ≤ 40% ja nad peavad olema stabiliseeritud kroonilise südamepuudulikkuse raviga.
English: Special caution is necessary when you are treated with a ßblocker concomitantly,
Estonian: Eriline ettevaatus on vajalik, kui teid ravitakse samal ajal beetablokaatoriga,
English: • other blood pressure lowering medicines as they may additionally reduce your blood pressure.
Estonian: • teised vererõhku langetavad ravimid, sest need võivad veelgi langetada teie vererõhku.
English: Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients.
Estonian: Losartaan mõjub sama tõhusalt nii nais- kui ka meespatsientidele, nii noorematele (vanus alla 65 aasta) kui ka vanematele hüpertensiooniga patsientidele.
English: Losartan may be administered with or without food.
Estonian: Losartaani võib manustada koos toiduga või ilma.
English: After that year the safety data will be evaluated and it will be decided whether a longer PSUR period is permitted.
Estonian: Pärast kõnealuse aasta ohutusandmete hindamist otsustatakse, kas perioodilist uusimate ohutusandmete aruannet võib esitada pikema ajavahemiku järel.
English: Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of medicinal products.
Estonian: Kuigi puuduvad kontrollitud epidemioloogilised andmed riski kohta angiotensiin II retseptori inhibiitoritega (AIIRAd), võivad selle ravimite klassi jaoks eksisteerida teised riskid.
English: Sorbitol/Fructose intolerance
Estonian: Sorbitooli/fruktoosi talumatus
English: This applies particularly when losartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function.
Estonian: See kehtib eriti siis, kui losartaani manustatakse teiste seisundite olemasolul (palavik, dehüdratsioon), mis halvendavad tõenäoliselt neerufunktsiooni.
English: The results showed roughly similar pharmacokinetic parameters of losartan following oral administration in infants and toddlers, preschool children, school-age children and adolescents.
Estonian: Tulemused näitasid üldjoontes samasuguseid losartaani farmakokineetilisi parameetreid pärast suukaudset manustamist imikutele ja väikelastele, eelkooliealistele lastele, kooliealistele lastele ja noorukitele.
English: COZAAR is unlikely to affect your ability to drive or use machines.
Estonian: COZAAR ei mõjuta tõenäoliselt autojuhtimise ega masinatega töötamise võimet.
English: For Healthcare providers only: See Package Leaflet for instructions on how to prepare Losartan potassium oral suspension.
Estonian: Ainult meditsiinipersonalile: vaadake pakendi infolehest istruktsiooni, kuidas valmistada losartaankaaliumi suukaudset suspensiooni.
English: What COZAAR contains
Estonian: Mida COZAAR sisaldab